Most Read News

Third-party cargo represented 49% of total, up from 40% in FY24, the result of greater reliance on non-captive business.

Of the total, ₹1,082 crore worth of projects were secured by the building division. The remaining ₹581 crore worth of orders were bagged by the transport division.

Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.

Revenue for the year increased 20% YoY to ₹4,829 crore, led by increased cargo tonnage and consolidation of acquired units.

The bank's core operating income, or net interest revenue (NII), rose 8.3% year on year at ₹2,377.4 crore, reflecting sustained business growth

USFDA's final approval is available for Zydus Lifesciences and group companies, and this will allow the group to sell the product in the highly regulated US market.

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US

Quarterly revenues were 28% higher year on year at ₹4,988.4 crore from ₹3,912.7 crore in Q4 FY24.

EBITDA margin also rose to 32.2%, compared to 30.9% last year corresponding quarter

Total operating revenue was ₹2,134 crore in the quarter even with last year overall, and showing steady sales in its core verticals